AstraZeneca shares fall on $39-billion Alexion bill
AstraZeneca shares fell 9% today as investors moved to price in the British drugmaker's $39 billion deal for US biotech firm Alexion Pharmaceuticals, the company's largest ever and one of this year's biggest mergers globally.
Business
• 14 Dec 20
